Skip to main content
Top
Published in: BMC Neurology 1/2009

Open Access 01-12-2009 | Debate

Understanding patients' perspective in the use of generic antiepileptic drugs: compelling lessons for physicians to improve physician/patient communication

Author: Kore Liow

Published in: BMC Neurology | Issue 1/2009

Login to get access

Abstract

Background

Epilepsy is a condition in which consistency of treatment is paramount to successful management and for most patients, effective seizure control can be achieved. Given the severe consequences of even a single breakthrough seizure, patients should be afforded every opportunity to succeed on their given regimens.

Discussion

Some experts argue that global policy on generic antiepileptic drug substitution in epilepsy should be limited – occurring at the discretion of and with careful monitoring by the physician. While the debate continues, physicians still have daily responsibilities to their patients to help them best manage their epilepsy within the context of the current environment – the reality of which may involve switching to a generic antiepileptic drug or navigating various formulations between generics.

Summary

To provide context, this paper first reviews the main "hot button" issues fueling the ongoing generic debate, including a broad overview of the current state of the literature. The main goal however is to provide physicians with a patient perspective on generic antiepileptic drug use in epilepsy as a source of clinically useful, everyday advice to improve communication and increase patient self-advocacy, both of which are necessary for optimal patient outcome.
Literature
1.
go back to reference Duh MS, Andermann F, Paradis PE, Weiner J, Manjunath R, Cremieux PY: The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: the case of lamotrigine. Dis Manag. 2007, 10 (4): 216-225. 10.1089/dis.2007.104649.CrossRefPubMed Duh MS, Andermann F, Paradis PE, Weiner J, Manjunath R, Cremieux PY: The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: the case of lamotrigine. Dis Manag. 2007, 10 (4): 216-225. 10.1089/dis.2007.104649.CrossRefPubMed
2.
go back to reference Kramer G, Biraben A, Carreno M, Guekht A, de Haan GJ, Jedrzejczak J, Josephs D, van Rijckevorsel K, Zaccara G: Current approaches to the use of generic antiepileptic drugs. Epilepsy Behav. 2007, 11 (1): 46-52. 10.1016/j.yebeh.2007.03.014.CrossRefPubMed Kramer G, Biraben A, Carreno M, Guekht A, de Haan GJ, Jedrzejczak J, Josephs D, van Rijckevorsel K, Zaccara G: Current approaches to the use of generic antiepileptic drugs. Epilepsy Behav. 2007, 11 (1): 46-52. 10.1016/j.yebeh.2007.03.014.CrossRefPubMed
3.
go back to reference Heaney DC, Sander JW: Antiepileptic drugs: generic versus branded treatments. Lancet Neurol. 2007, 6 (5): 465-468. 10.1016/S1474-4422(07)70105-9.CrossRefPubMed Heaney DC, Sander JW: Antiepileptic drugs: generic versus branded treatments. Lancet Neurol. 2007, 6 (5): 465-468. 10.1016/S1474-4422(07)70105-9.CrossRefPubMed
4.
go back to reference Assessment: generic substitution for antiepileptic medication. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 1990, 40 (11): 1641-1643. Assessment: generic substitution for antiepileptic medication. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 1990, 40 (11): 1641-1643.
5.
go back to reference Jobst BC, Holmes GL: Prescribing antiepileptic drugs: should patients be switched on the basis of cost?. CNS Drugs. 2004, 18 (10): 617-628. 10.2165/00023210-200418100-00001.CrossRefPubMed Jobst BC, Holmes GL: Prescribing antiepileptic drugs: should patients be switched on the basis of cost?. CNS Drugs. 2004, 18 (10): 617-628. 10.2165/00023210-200418100-00001.CrossRefPubMed
6.
go back to reference Berg MJ, Gross RA: Physicians and patients percive that generic drug substitution of antiepileptic drugs can cause breakthrough seizures: results from a US survey. Epilepsia. 2006, 47 (Suppl 4): 155- Berg MJ, Gross RA: Physicians and patients percive that generic drug substitution of antiepileptic drugs can cause breakthrough seizures: results from a US survey. Epilepsia. 2006, 47 (Suppl 4): 155-
7.
go back to reference Berg MJ, Gross RA, Tomaszewski KJ, Zingaro WM, Haskins LS: Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures. Neurology. 2008, 71 (7): 525-530. 10.1212/01.wnl.0000319958.37502.8e.CrossRefPubMed Berg MJ, Gross RA, Tomaszewski KJ, Zingaro WM, Haskins LS: Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures. Neurology. 2008, 71 (7): 525-530. 10.1212/01.wnl.0000319958.37502.8e.CrossRefPubMed
8.
go back to reference Guberman A, Corman C: Generic substitution for brand name antiepileptic drugs: a survey. Can J Neurol Sci. 2000, 27 (1): 37-43.PubMed Guberman A, Corman C: Generic substitution for brand name antiepileptic drugs: a survey. Can J Neurol Sci. 2000, 27 (1): 37-43.PubMed
9.
go back to reference Haskins LS, Tomaszewski KJ, Crawford P: Patient and physician reactions to generic antiepileptic substitution in the treatment of epilepsy. Epilepsy Behav. 2005, 7 (1): 98-105. 10.1016/j.yebeh.2005.04.005.CrossRefPubMed Haskins LS, Tomaszewski KJ, Crawford P: Patient and physician reactions to generic antiepileptic substitution in the treatment of epilepsy. Epilepsy Behav. 2005, 7 (1): 98-105. 10.1016/j.yebeh.2005.04.005.CrossRefPubMed
10.
go back to reference Wilner AN: Therapeutic equivalency of generic antiepileptic drugs: results of a survey. Epilepsy Behav. 2004, 5 (6): 995-998. 10.1016/j.yebeh.2004.05.011.CrossRefPubMed Wilner AN: Therapeutic equivalency of generic antiepileptic drugs: results of a survey. Epilepsy Behav. 2004, 5 (6): 995-998. 10.1016/j.yebeh.2004.05.011.CrossRefPubMed
11.
go back to reference National Association of Boards of Pharmacy: Survey of pharmacy law. 2006, Mount Prospect, IL National Association of Boards of Pharmacy: Survey of pharmacy law. 2006, Mount Prospect, IL
12.
go back to reference Berg MJ: What's the problem with generic antiepileptic drugs?: a call to action. Neurology. 2007, 68 (16): 1245-1246. 10.1212/01.wnl.0000262876.37269.8b.CrossRefPubMed Berg MJ: What's the problem with generic antiepileptic drugs?: a call to action. Neurology. 2007, 68 (16): 1245-1246. 10.1212/01.wnl.0000262876.37269.8b.CrossRefPubMed
13.
go back to reference Borgheini G: The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. Clin Ther. 2003, 25 (6): 1578-1592. 10.1016/S0149-2918(03)80157-1.CrossRefPubMed Borgheini G: The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. Clin Ther. 2003, 25 (6): 1578-1592. 10.1016/S0149-2918(03)80157-1.CrossRefPubMed
14.
go back to reference Crawford P, Feely M, Guberman A, Kramer G: Are there potential problems with generic substitution of antiepileptic drugs? A review of issues. Seizure. 2006, 15 (3): 165-176. 10.1016/j.seizure.2005.12.010.CrossRefPubMed Crawford P, Feely M, Guberman A, Kramer G: Are there potential problems with generic substitution of antiepileptic drugs? A review of issues. Seizure. 2006, 15 (3): 165-176. 10.1016/j.seizure.2005.12.010.CrossRefPubMed
16.
go back to reference Wolf P: Political Campaign in Denmark. Epilepsia. 2007, 49 (Suppl 7): 6- Wolf P: Political Campaign in Denmark. Epilepsia. 2007, 49 (Suppl 7): 6-
17.
go back to reference Nielsen KA, Dahl M, Tommerup E, Wolf P: Comparative daily profiles with different preparations of lamotrigine: a pilot investigation. Epilepsy Behav. 2008, 13 (1): 127-130. 10.1016/j.yebeh.2008.02.020.CrossRefPubMed Nielsen KA, Dahl M, Tommerup E, Wolf P: Comparative daily profiles with different preparations of lamotrigine: a pilot investigation. Epilepsy Behav. 2008, 13 (1): 127-130. 10.1016/j.yebeh.2008.02.020.CrossRefPubMed
18.
go back to reference Besag FM: Is generic prescribing acceptable in epilepsy?. Drug Saf. 2000, 23 (3): 173-182. 10.2165/00002018-200023030-00001.CrossRefPubMed Besag FM: Is generic prescribing acceptable in epilepsy?. Drug Saf. 2000, 23 (3): 173-182. 10.2165/00002018-200023030-00001.CrossRefPubMed
19.
go back to reference Berg MJ, Gross RA, Haskins LS, Zingaro WM, Tomaszewski KJ: Generic substitution in the treatment of epilepsy: Patient and physician perceptions. Epilepsy Behav. 2008, 13 (4): 693-699. 10.1016/j.yebeh.2008.06.001.CrossRefPubMed Berg MJ, Gross RA, Haskins LS, Zingaro WM, Tomaszewski KJ: Generic substitution in the treatment of epilepsy: Patient and physician perceptions. Epilepsy Behav. 2008, 13 (4): 693-699. 10.1016/j.yebeh.2008.06.001.CrossRefPubMed
20.
go back to reference Hartley R, Aleksandrowicz J, Ng PC, McLain B, Bowmer CJ, Forsythe WI: Breakthrough seizures with generic carbamazepine: a consequence of poorer bioavailability?. Br J Clin Pract. 1990, 44 (7): 270-273.PubMed Hartley R, Aleksandrowicz J, Ng PC, McLain B, Bowmer CJ, Forsythe WI: Breakthrough seizures with generic carbamazepine: a consequence of poorer bioavailability?. Br J Clin Pract. 1990, 44 (7): 270-273.PubMed
21.
go back to reference MacDonald JT: Breakthrough seizure following substitution of Depakene capsules (Abbott) with a generic product. Neurology. 1987, 37 (12): 1885-CrossRefPubMed MacDonald JT: Breakthrough seizure following substitution of Depakene capsules (Abbott) with a generic product. Neurology. 1987, 37 (12): 1885-CrossRefPubMed
22.
go back to reference Meyer MC, Straughn AB: Biopharmaceutical factors in seizure control and drug toxicity. Am J Hosp Pharm. 1993, 50 (12 Suppl 5): S17-22.PubMed Meyer MC, Straughn AB: Biopharmaceutical factors in seizure control and drug toxicity. Am J Hosp Pharm. 1993, 50 (12 Suppl 5): S17-22.PubMed
23.
go back to reference Bialer M: Generic products of antiepileptic drugs (AEDs): is it an issue?. Epilepsia. 2007, 48 (10): 1825-1832. 10.1111/j.1528-1167.2007.01272.x.CrossRefPubMed Bialer M: Generic products of antiepileptic drugs (AEDs): is it an issue?. Epilepsia. 2007, 48 (10): 1825-1832. 10.1111/j.1528-1167.2007.01272.x.CrossRefPubMed
24.
go back to reference LeLorier J, Duh MS, Paradis PE, Lefebvre P, Weiner J, Manjunath R, Sheehy O: Clinical consequences of generic substitution of lamotrigine for patients with epilepsy. Neurology. 2008, 70 (22 Pt 2): 2179-2186. 10.1212/01.wnl.0000313154.55518.25.CrossRefPubMed LeLorier J, Duh MS, Paradis PE, Lefebvre P, Weiner J, Manjunath R, Sheehy O: Clinical consequences of generic substitution of lamotrigine for patients with epilepsy. Neurology. 2008, 70 (22 Pt 2): 2179-2186. 10.1212/01.wnl.0000313154.55518.25.CrossRefPubMed
25.
go back to reference Privitera MD: Generic antiepileptic drugs: current controversies and future directions. Epilepsy Currents. 2008, 8 (5): 113-117. 10.1111/j.1535-7511.2008.00261.x.CrossRefPubMedPubMedCentral Privitera MD: Generic antiepileptic drugs: current controversies and future directions. Epilepsy Currents. 2008, 8 (5): 113-117. 10.1111/j.1535-7511.2008.00261.x.CrossRefPubMedPubMedCentral
26.
go back to reference Papsdorf TB, Ablah E, Ram S, Sadler T, Liow K: Patient perception of generic antiepileptic drugs in the Midwestern United States. Epilepsy Behav. 2008, Papsdorf TB, Ablah E, Ram S, Sadler T, Liow K: Patient perception of generic antiepileptic drugs in the Midwestern United States. Epilepsy Behav. 2008,
27.
go back to reference Kramer G, Steinhoff BJ, Feucht M, Pfafflin M, May TW: Experience with generic drugs in epilepsy patients: an electronic survey of members of the German, Austrian and Swiss branches of the ILAE. Epilepsia. 2007, 48 (3): 609-611. 10.1111/j.1528-1167.2007.01084_1.x.CrossRefPubMed Kramer G, Steinhoff BJ, Feucht M, Pfafflin M, May TW: Experience with generic drugs in epilepsy patients: an electronic survey of members of the German, Austrian and Swiss branches of the ILAE. Epilepsia. 2007, 48 (3): 609-611. 10.1111/j.1528-1167.2007.01084_1.x.CrossRefPubMed
28.
go back to reference Liow K, Barkley GL, Pollard JR, Harden CL, Bazil CW: Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy. Neurology. 2007, 68 (16): 1249-1250. 10.1212/01.wnl.0000259400.30539.cc.CrossRefPubMed Liow K, Barkley GL, Pollard JR, Harden CL, Bazil CW: Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy. Neurology. 2007, 68 (16): 1249-1250. 10.1212/01.wnl.0000259400.30539.cc.CrossRefPubMed
29.
go back to reference Perucca E, Albani F, Capovilla G, Bernardina BD, Michelucci R, Zaccara G: Recommendations of the Italian League against Epilepsy working group on generic products of antiepileptic drugs. Epilepsia. 2006, 47 (Suppl 5): 16-20. 10.1111/j.1528-1167.2006.00871.x.CrossRefPubMed Perucca E, Albani F, Capovilla G, Bernardina BD, Michelucci R, Zaccara G: Recommendations of the Italian League against Epilepsy working group on generic products of antiepileptic drugs. Epilepsia. 2006, 47 (Suppl 5): 16-20. 10.1111/j.1528-1167.2006.00871.x.CrossRefPubMed
30.
go back to reference Feely M, Crawford P, Kramer G, Guberman A: Risk management in epilepsy: generic substitution and continuity of supply. The European Journal of Hospital Pharmacy Science. 2005, 68 (16): 1249-1250. Feely M, Crawford P, Kramer G, Guberman A: Risk management in epilepsy: generic substitution and continuity of supply. The European Journal of Hospital Pharmacy Science. 2005, 68 (16): 1249-1250.
31.
go back to reference Wyllie E, Pippenger CE, Rothner AD: Increased seizure frequency with generic primidone. JAMA. 1987, 258 (9): 1216-1217. 10.1001/jama.258.9.1216.CrossRefPubMed Wyllie E, Pippenger CE, Rothner AD: Increased seizure frequency with generic primidone. JAMA. 1987, 258 (9): 1216-1217. 10.1001/jama.258.9.1216.CrossRefPubMed
32.
go back to reference Mikati M, Bassett N, Schachter S: Double-blind randomized study comparing brand-name and generic phenytoin monotherapy. Epilepsia. 1992, 33 (2): 359-365. 10.1111/j.1528-1157.1992.tb02328.x.CrossRefPubMed Mikati M, Bassett N, Schachter S: Double-blind randomized study comparing brand-name and generic phenytoin monotherapy. Epilepsia. 1992, 33 (2): 359-365. 10.1111/j.1528-1157.1992.tb02328.x.CrossRefPubMed
33.
go back to reference Oles KS, Penry JK, Smith LD, Anderson RL, Dean JC, Riela AR: Therapeutic bioequivalency study of brand name versus generic carbamazepine. Neurology. 1992, 42 (6): 1147-1153.CrossRefPubMed Oles KS, Penry JK, Smith LD, Anderson RL, Dean JC, Riela AR: Therapeutic bioequivalency study of brand name versus generic carbamazepine. Neurology. 1992, 42 (6): 1147-1153.CrossRefPubMed
34.
go back to reference Andermann F, Duh MS, Gosselin A, Paradis PE: Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia. 2007, 48 (3): 464-469. 10.1111/j.1528-1167.2007.01007.x.CrossRefPubMed Andermann F, Duh MS, Gosselin A, Paradis PE: Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia. 2007, 48 (3): 464-469. 10.1111/j.1528-1167.2007.01007.x.CrossRefPubMed
35.
go back to reference Dilorio C, Faherty B, Manteuffel B: Learning needs of persons with epilepsy: a comparison of perceptions of persons with epilepsy, nurses and physicians. J Neurosci Nurs. 1993, 25 (1): 22-29.CrossRefPubMed Dilorio C, Faherty B, Manteuffel B: Learning needs of persons with epilepsy: a comparison of perceptions of persons with epilepsy, nurses and physicians. J Neurosci Nurs. 1993, 25 (1): 22-29.CrossRefPubMed
36.
go back to reference Lowes R: Patient-centered care for better patient adherence. Fam Pract Manag. 1998, 5 (3): 46-47. 51-44, 57PubMed Lowes R: Patient-centered care for better patient adherence. Fam Pract Manag. 1998, 5 (3): 46-47. 51-44, 57PubMed
37.
go back to reference Schachter SC: Antiepileptic drug therapy: general treatment principles and application for special patient populations. Epilepsia. 1999, 40 (Suppl 9): S20-25. 10.1111/j.1528-1157.1999.tb02090.x.CrossRefPubMed Schachter SC: Antiepileptic drug therapy: general treatment principles and application for special patient populations. Epilepsia. 1999, 40 (Suppl 9): S20-25. 10.1111/j.1528-1157.1999.tb02090.x.CrossRefPubMed
38.
go back to reference Schachter SC: Epilepsy: Quality of Life and Cost of Care. Epilepsy Behav. 2000, 1 (2): 120-127. 10.1006/ebeh.2000.0049.CrossRefPubMed Schachter SC: Epilepsy: Quality of Life and Cost of Care. Epilepsy Behav. 2000, 1 (2): 120-127. 10.1006/ebeh.2000.0049.CrossRefPubMed
39.
go back to reference Busch RL: Generic carbamazepine and erythema multiforme: generic-drug nonequivalency. N Engl J Med. 1989, 321 (10): 692-693.CrossRefPubMed Busch RL: Generic carbamazepine and erythema multiforme: generic-drug nonequivalency. N Engl J Med. 1989, 321 (10): 692-693.CrossRefPubMed
40.
go back to reference Sachdeo RC, Belendiuk G: Generic versus branded carbamazepine. Lancet. 1987, 1 (8547): 1432-10.1016/S0140-6736(87)90619-2.CrossRefPubMed Sachdeo RC, Belendiuk G: Generic versus branded carbamazepine. Lancet. 1987, 1 (8547): 1432-10.1016/S0140-6736(87)90619-2.CrossRefPubMed
41.
go back to reference Hovinga CA, Asato MR, Manjunath R, Wheless JW, Phelps SJ, Sheth RD, Pina-Garza JE, Zingaro WM, Haskins LS: Association of non-adherence to antiepileptic drugs and seizures, quality of life, and productivity: survey of patients with epilepsy and physicians. Epilepsy Behav. 2008, 13 (2): 316-322. 10.1016/j.yebeh.2008.03.009.CrossRefPubMed Hovinga CA, Asato MR, Manjunath R, Wheless JW, Phelps SJ, Sheth RD, Pina-Garza JE, Zingaro WM, Haskins LS: Association of non-adherence to antiepileptic drugs and seizures, quality of life, and productivity: survey of patients with epilepsy and physicians. Epilepsy Behav. 2008, 13 (2): 316-322. 10.1016/j.yebeh.2008.03.009.CrossRefPubMed
42.
go back to reference UCB Compliance Survey: Analysis and Takeaways. 2008, Conducted by Rosetta UCB Compliance Survey: Analysis and Takeaways. 2008, Conducted by Rosetta
43.
go back to reference Wolf P: Should newly diagnosed epilepsy be treated with generics?. Nat Clin Pract Neurol. 2008, 4 (4): 176-177.PubMed Wolf P: Should newly diagnosed epilepsy be treated with generics?. Nat Clin Pract Neurol. 2008, 4 (4): 176-177.PubMed
44.
go back to reference AED and Continuity of Supply: Consideration for Patients. Conducted by UCB, Inc.; Transcripts from Patient Forum held March 30, 2008, Washington, D.C AED and Continuity of Supply: Consideration for Patients. Conducted by UCB, Inc.; Transcripts from Patient Forum held March 30, 2008, Washington, D.C
45.
go back to reference The President's Advisory Commission on Consumer Protection and Quality in the Health Care Industry: Consumer Bill of Rights and Responsibilities. Report to the President of the United States. 1997, Washington, DC: The President's Advisory Commission on Consumer Protection and Quality in the Health Care Industry The President's Advisory Commission on Consumer Protection and Quality in the Health Care Industry: Consumer Bill of Rights and Responsibilities. Report to the President of the United States. 1997, Washington, DC: The President's Advisory Commission on Consumer Protection and Quality in the Health Care Industry
46.
go back to reference Sipkoff M: The epilepsy battle in the war between brands and generics. Manag Care. 2008, 17 (3): 24-27. Sipkoff M: The epilepsy battle in the war between brands and generics. Manag Care. 2008, 17 (3): 24-27.
47.
go back to reference National Association of Boards of Pharmacy: Survey of Pharmacy Laws. XIX. Drug product selection laws. 2006 National Association of Boards of Pharmacy: Survey of Pharmacy Laws. XIX. Drug product selection laws. 2006
48.
go back to reference Christensen TP, Kirking DM, Ascione FJ, Welage LS, Gaither CA: Drug product selection: legal issues. J Am Pharm Assoc (Wash). 2001, 41 (6): 868-874.CrossRef Christensen TP, Kirking DM, Ascione FJ, Welage LS, Gaither CA: Drug product selection: legal issues. J Am Pharm Assoc (Wash). 2001, 41 (6): 868-874.CrossRef
49.
go back to reference Vivian JC: Generic-Substitution Laws. US Pharmacist. 2008, 33 (6): 30-34. Vivian JC: Generic-Substitution Laws. US Pharmacist. 2008, 33 (6): 30-34.
50.
go back to reference Cassell DK: Should generic substitution of antiepileptic drugs be restricted?. Drug Topics Suppl. 2007, Aug 6 Cassell DK: Should generic substitution of antiepileptic drugs be restricted?. Drug Topics Suppl. 2007, Aug 6
51.
go back to reference Argumosa A, Herranz JL: The clinical and economic impact of generic drugs in the treatment of epilepsy. Rev Neurol. 2005, 41 (1): 45-49.PubMed Argumosa A, Herranz JL: The clinical and economic impact of generic drugs in the treatment of epilepsy. Rev Neurol. 2005, 41 (1): 45-49.PubMed
Metadata
Title
Understanding patients' perspective in the use of generic antiepileptic drugs: compelling lessons for physicians to improve physician/patient communication
Author
Kore Liow
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2009
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/1471-2377-9-11

Other articles of this Issue 1/2009

BMC Neurology 1/2009 Go to the issue